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1. Introduction 
Chromaffin granules, the catecholamine storage 
organelles of adrenal medulla, accumulate monoamines 
by an active process which involves 2 different entities: 
an electrogenic ATP-dependent H+ctranslocase which 
generates a proton electrochemical gradient ApH+ 
(interior acid and positive) [l-3] and a specific 
monoamine carrier which mediates the coupling 
between Ac(H+ and substrate accumulation [4-61. 
Kinetics and pharmacological properties of the latter 
have been described [7,8], but little is known about 
its biochemistry. Diethylpyrocarbonate ,a histidine 
specific reagent, has been shown to affect lactose/H+ 
symport in Escherichia coli membranes by directly 
reacting with the lac carrier [9]. A similar eaction 
was reported for proline and D-lactate transport [9]. 
We investigated the possibility that DEPC might also 
react with the monoamine carrier of chromaffm 
granule membranes. Monoamine/proton antiport was 
assayed independently of the H’-translocase by 
imposing a pH-gradient (interior acid) on chromaffm 
granule ghosts [5,8,10]. 
gifts of Dr A. Stempel (Hoffman-La Roche) and Dr 
B. S. Cooperman, respectively. [3H]Dihydrotetra- 
benazine (12 Ci/mmol) was prepared as in [ 111. 
S-Hydroxy [G-3H]tryptamine creatinine sulfate (18 
Ci/mmol), l-[7,8-3H]Noradrenaline (12 Cijmmol), 
[7-14C] tyramine hydrochloride (50 mCi/mmol) were 
from Amersham, [ 14C] methylamine hydrochloride 
(38 mCi/mmol) was from CEA. 
2.2. Chromaffin granule ghosts 
Ghosts were derived from purified chromaffm 
granules by hypoosmotic lysis [ 121, frozen in liquid 
nitrogen and stored at -80°C. 
2.3. DEPC-treatment of membranes 
2. Materials and methods 
2.1. Materials 
DEFT was purchased from Sigma. Stock solutions 
(120 mM) were prepared in absolute thanol and 
were used immediately. Nigericin and OX-V were 
Membranes were thawed diluted by 3 vol. water, 
centrifuged for 15 min at full speed in an Airfuge 
centrifuge (Beckman) and resuspended at4-5 mg 
protein/ml in 10 mM potassium phosphate buffer 
(pH 6.0) containing 0.15 M KC1 (buffer A). DEPC 
(generally 1.2 mM, final cont.) or absolute thanol 
(l%, final cont.) were added under stirring and the 
mixture was kept at room temperature for 15 min. 
When nigericin and K’ were used to generate the pH- 
gradient [131 the mixture was diluted -20-fold in 
10 mM Tris-Hepes buffer (PH 7.5) containing 0.15 M 
KC1 (buffer B), centrifuged at 160 000 X gav for 
20 min and resuspended at lo-20 mg protein/ml in 
the same buffer. When nigericin was not used, sam- 
ples were washed in buffer A or, where indicated, in a 
similar buffer in which K’ was substituted for by Na’. 
Abbreviations: DEPC, diethylpyrocarbonate; OX-V, bis 
(3-phenyl-5-oxoisoxazol4yl) pentamethine oxonol; Hepes, 
N-Zhydroxyethyl piperazine-M-2 ethane sulfonic acid; Mes, 
2-(N-morpholino) ethanesulfonic acid; 5-HT, S-hydroxytrypt- 
amine 
2.4. ApHdriven monoamine uptake 
Nigericin was routinely used to generate pH-gradi- 
ent [ 131, Membranes resealed in buffer B (5 /,d aliquots 
containing 0.05 -0.1 mg protein) were diluted 1 00-fold 
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in 10 mM Tris-Hepes (pH 8.5) containing 0.3 M 
sucrose, 2 mM MgS04, 10 PM nigericin and 1 @i 
[3H]noradrenaline or 5-t3H]HT (-500 000 cpm). 
Controls contained in addition 20 PM tetrabenazine. 
Samples were incubated at 37”C, diluted by 1 ml ice- 
cold 0.3 M sucrose, 10 mM Tris-Hepes buffer (pH 8.5) 
and filtered on HAWP Millipore filters. Filters were 
washed twice with 2 ml of the same buffer and their 
radioactivity measured in 5 ml either toluene-PPO- 
POPOP (after drying) or Aqualuma (without drying). 
Results were corrected for non-carrier mediated 
amine retention by subtracting control values mea- 
sured in presence of tetrabenazme. 
2.5. Analytical techniques 
ATPaselactivity was measured as in [12]. Potential 
measurements with the probe OX-V were performed 
as in [14]. [3H]Dihydrotetrabenazine binding was 
estimated by the centrifugation technique [111. Pro- 
teins were assayed by the Lowry procedure. 
3. Results 
3 .l . Effect of DEPC treatment on ApHdriven 
monoamine uptake 3.2. Effect of DEPC on passive properties of 
DEPC-treatment inhibited both initial rate and 
plateau level of monoamine uptake driven by a pH- 
gradient (inside acidic) (fig.1). The inhibition was 
often visible after a 10 s lag (see fig2A, inset). With 
both noradrenaline and 5-HT as the transported 
amine, inhibition of the rate of uptake was repeatedly 
in the 30-70% range under various experimental 
conditions. Maximal effect required -1.2 mM 
DEPC (fig.‘LB). The figure also shows the effect of 
DEPC on ghost ATPase and on the ATP-induced 
fluorescence changes of the extrinsic probe OX-V, 
which monitored transmembrane potentials genera- 
tion by the ATP-driven H’-translocase [ 141. Both 
activities were inhibited by the reagent in the same 
concentration range as monoamine uptake. 
chromaffin granule membrane 
The inactivation of 5HT uptake by 1.2 mM DEPC 
was relatively independent of pH over 6.0-8.5, 
increasing from 50% at pH 6.0 to 70% at pH 7.5 (not 
shown). The reaction was routinely performed at 
pH 6.0 since N-ethoxyformyl derivatives are more 
stable at acidic pH [ 151. Under these conditions, the 
inhibition was slow (fig.2A). 
Since DEPC certainly modified various components 
of the membrane (see fig2B), it was of interest o 
test if monoamine uptake inhibition did not originate 
in a non-specific hange of the membrane properties. 
Methylamine isaccumulated by ghosts which have an 
internal space acidic with respect to the medium [161. 
This transport is not carrier-mediated [8] and it can 
be utilized to measure transmembrane pH-gradients 
[ 11. Methylamine uptake was not affected in DEPC- 
treated vesicles (fig.3), indicating that modified mem- 
branes monitored pH-gradients similar to controls. 
The effect of DEPC on ApH-driven tyramine uptake 
was next investigated. Tyramine is not transported by 
the tetrabenazine-sensitive monoamine carrier when 
ghosts are energized by an imposed pH gradient [8] 
and this amine can thus be considered as a pH-probe. 
ApH-driven tyramine uptake by DEPC-treated mem- 
branes was resistant to 10 @I tetrabenazine and was 
85% of control values with untreated vesicles, provid- 
ing strong evidence for the argument that passive 
properties of the membrane were not modified. 
Time (s) 
Fig.1. ApHdriven uptake of S-HT by DEPC-treated mem- 
branes. Membranes were treated by 2 mM DEPC (o) or by 1% 
ethanol (0). S-HT uptake was measured in presence of nigericin 
(see section 2.4). 
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Fig.2. Timecourse and dose-dependency of DEPC-modification. (A) Membranes were incubated with 1.2 mM DEPC at room tem- 
perature for the indicated period of time. They were washed and assayed for S-HT uptake in presence of nigericin. Results are 
expressed as inhibition of the rate of uptake. Inset: Time-course of S-HT uptake by modified membranes. (B) Membranes were 
treated with the indicated concentration of DEPC for 15 mm at room temperature. 5-HT uptake (o), ATPase activity (A), and 
ATP-induced OX-V fluorescence change (0) inhibitions were measured in the same sampies. 
The permeability to K’ of the membrane was 
investigated (fig.4), using the fluorescence of OX-V to 
monitor transmembrane potential [ 141. Addition of 
K$304 (50 mM) did not polarize positively control 
or DEPC-treated ghosts resealed in a Na’-containing 
medium. Such an effect was observed after addition 0 
of the K’-ionophore valinomycin and was similar with b 
both preparations. The lack of polarization in absence 
of the ionophore showed that DEPC did not increase 
; 
e 
the K’ permeability of the membrane. 
The absence of changes in the passive properties 
of the membrane suggested that DEPC altered the 
9 
monoamine carrier. We were nevertheless unable to 
5 
demonstrate a change of reactivity to DEPC associated e ._ 
E 
,o 
2 
Fig.3. Methylamine uptake by DEPC-treated membranes. 
Control (0) and treated membranes (0) were resuspended in I 
buffer A. Aliquots (10 ~1) were diluted 20-fold in 10 mM 
Tris-Hepes @H 9.2) containing 0.3 M sucrose and [“Cl- 
methylamine (0.16 &i); final pH was 8.7. After incubation 
at 22’C, samples were processed as described for monoamine 
uptake, the radioactivity of the falters being measured without 
I 
OO 
I I I I I I 
20 40 60 
drying in 5 ml Aqualuma. Time (s) 
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Fig.4. Effect of DEPC-treatment on g-induced OX-V effect. 
Membranes were treated for 15 min with 1% ethanol (A) or 
with 1.2 mM DEPC (B), as in section 2.3 but with Na+ sub- 
stituted for K’ in buffer A. The cuvette contained in 2 ml 
final volume: 140 Mug protein of control (A) or DEPC-treated 
(B) membranes resealed in Na+containing buffer, 1 PM OX-V, 
0.3 M sucrose and 20 mM Mes-NaOH buffer (pH 6.6). After 
3 min at 22’C, 500 mM K,SO, (200 ~1) was added, followed 
by 4 mM valinomycin (5 ~1). Fluorescence (ext. 580 nm, em. 
650 nm) was measured with a JY 3 C Jobin-Yvon fluorimeter. 
Relative fluorescence changes after valmomycin addition 
were 59.8% and 62.5% for control and DEPC-treated mem- 
branes respectively. 
with protection or energization of the monoamine 
transporter. Noradrenaline (0.5 mM) did not protect 
membranes from inactivation by treatment at pH 7.6 
with 1.2 mM DEPC. Energization of the vesicles by 
addition of 0.5 or 1 mM ATP prior to the addition 
of 2 mM DFPC did not rrhiurp 5 4-U up&e inhibition. 
3.3. Effect of imposed transmembrane potentials 
A\k on ApHdriven monoamine uptake by 
DEPC-treated membranes 
We [6] and others [ 17,181 have shown that A’@ 
superimposed on pH-gradients changed noradrenaline 
rate of uptake. When the vesicle interior was polarized 
positively by treatment of the ghost membrane with 
valinomycin and addition of K2S04 to the medium, 
the rate of uptake was increased. This experiment was 
repeated with DEPC-treated preparations. A positive 
polarization enhanced the rate of uptake of 5.HT 
(fig.SA) or noradrenaline (not shown) by modified 
vesicles. The stimulation factor was about the same or 
slightly higher with DEPC-treated than with controls 
(1.5 -4.fold stimulation). Consequently the rate of 
uptake measured in presence of both a ApH and a 
positive A\k was also inhibited by DEPC-treatment. 
We had shown that ghosts negatively polarized by a 
suitable K’ gradient took up noradrenaline ata 
decreased rate [6]. This property was also shared by 
DEPC-treated vesicles (fig.SB). 
3.4. Kinetics of noradrenaline uptake in DEPC-treated 
vesicles 
Kinetics of ApH-driven oradrenaline uptake by 
DEPC-treated or control vesicles have been examined 
(table 1). The pH gradient was generated either by 
resuspension atpH 8.5 of ghosts resealed at pH 6.0 
(exp. 1) or by nigericin in presence of external K’ 
ions (exp. 2). Under the two sets of conditions, V,, 
was decreased by DEPC-treatment whereas Km was 
not significantly altered. 
3.5. Binding of [ 3H]dihydrotetrabenazine 
[‘HlDihydrotetrabenazine, a derivative of the 
potent uptake inhibitor tetrabenazine, binds to satu- 
rable sites on chromaffm granule membranes [ 111. 
Treatment of the membranes with DEPC changed 
neither the equilibrium dissociation constant Kd nor 
the number of binding sites (table 1). 
4. Discussion 
DEPC-treatment has been shown to inhibit ApH- 
driven monoamine uptake. This effect is not due to 
an inhibition of the ATPdependent H+-translocase 
since the H’-pump was by-passed under the described 
conditions of uptake. It is not an artefact of the 
uptake assay since: 
(i) Membranes were washed before being assayed; 
(ii) Similar inhibitions were observed when pH-gra- 
dients were generated either by resealing hosts 
at acidic pH or by a K*-gradient in presence of 
nigericin. 
A more rapid dissipation of the pH-gradient in DEPC- 
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Fig.5. Effect of transmeinbrane potentials on ApHdriven monoamine uptake. (A) Effect of a positive A*. Membranes were 
treated as in section 2 but with Na+ substituted for K’ in buffer A and were washed in the same buffer. DEPC-treated (o,A) and 
control (0,~) membranes were assayed in presence (A+) or in absence (o,o) of a positive A* induced by valmomycin. The incuba- 
tion mixture (200 ~1) contained: 70 I.rg protein, 1 NM 5-HT (300 000 cpm), 0.3 M sucrose, 100 mM Hepes-KOH (pH 8.5) and, 
where indicated (A$) 5 PM valinomycin. (B) Effect of a negative ArJI. Membranes were treated and washed in buffer A (K’ 
medium). Symbols are as in (A). The incubation mixture contained in 500 ~1: 130 pg protein, 1 PM noradrenaiine (X 10” cpm), 
2 mM MgSO,, 0.3 M sucrose, 10 mM Tris-Hepes buffer to give a fmal pH of 8.5 and, where indicated (~,a) 5 /&I valinomycin. 
Table 1 
Effect of DEPC-treatment on noradrenaline uptake kinetics and 
[ 3H Jdihydrotetrabenazine binding 
Control DEPC-treated 
Uptake of noradrenaline 
Expt la 
Km 01M) 
V max (pm01 . mm-‘. mg protein-‘) 
Expt 2b 
Km CUM) 
Vmax (pm01 . mm-‘. mg protein-‘) 
25 20 
4000 2400 
9.1 10.6 
2630 920 
Binding of dihydrotetrabenazineC 
Kd CuM) 
Emax (pmol/mg) 
0.07 0.062 
155 153 
a Expt 1 was performed as in tig.SA without valinomycin addition, but with 
noradrenaline as the substrate 
b Expt 2: noradrenaline uptake was measured in presence of nigericin 
’ Tetrabenazine binding was measured on membranes treated in buffer A and 
washed by buffer B 
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treated vesicles than in controls can be ruled out 
since methylamine and tyramine uptakes, which 
depend only on the transmembrane pH-difference 
[B], were similar for both preparations. Acceleration 
of catecholamine l akage in modified vesicles is 
unlikely since initial rates of uptake were considered 
and since tyramine accumulation was unaffected. 
Indirect electrogenic effects, e.g., negative polariza- 
tion of the DEPC-treated ghosts, is not a possible 
explanation in all experimental situations ince inhibi- 
tion was observed in sucrose or in ionic media, with 
symmetrical or asymmetrical distributions of the ions. 
Moreover DEPC did not increase the K’ permeability 
of the membrane (fig.4). Therefore we tentatively 
propose that DEPC modifies the monoamine carrier. 
Other reagents which inhibit ApH-driven monoamine 
uptake have been reported, but their site of action 
has not been characterized [ 191 or their effect is 
reversible, .g., reserpine [20] or tetrabenazine (unpub- 
lished) . 
If [3H] tetrabenazine binding sites are assumed to 
be the active site(s) of the monoamine carrier [ 111, 
the lack of effect of DEPC on Kd and B,, suggests 
that substrate binding is unaffected by the chemical 
modification. The absence of protection by the sub- 
strate supports this hypothesis. The observed ecrease 
Of ‘max would then indicate that the rate or the 
nature of the limiting step has been affected, directly 
or indirectly, by DEPC-treatment. I  has to be noted 
that electroneutral nd electrogenic uptakes were 
similarly inhibited, suggesting a common limiting step 
for both processes. The determination of the nature 
of this step will require more information. 
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